Build status - In Progress

Evaluating Treatment Management of Atrial Fibrillation with the BWI IRE Ablation System

Recruiting
18 years - 75 years
All
20 participants needed
1 Location

Brief description of study

The purpose of this study is to provide information about the safety and long-term effectiveness of the BWI irreversible electroporation (IRE) ablation system consisting of the TRUPULSE™ Generator and VARIPULSE™ Catheter. The Biosense Webster Inc. (BWI) IRE Ablation system is being studied for use in the treatment of Paroxysmal Atrial Fibrillation (PAF) in subjects who have failed at least one antiarrhythmic drug (medication to treat symptoms of PAF). The BWI IRE Ablation system is an investigational device that has not been approved by the FDA for the treatment of PAF.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research,
  • Age: 18 years - 75 years
  • Gender: All

Have Paroxysmal Atrial Fibrillation (PAF), which is causing your palpitations, chronic fatigue, weakness, shortness of breath, or pain. Age 18 to 75

Updated on 04 Aug 2024. Study ID: 851240

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center